Axogen, Inc. (AXGN)
Axogen, Inc. (AXGN) from its SEC filings: 2025 revenue $225.2 million (+20% vs the year before), net margin -7%, free cash flow -$2.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Electromedical & Electrotherapeutic Apparatus |
| Revenue (2025) | $225.2 million |
| Revenue growth | +20% |
| Net income | -$15.7 million |
| Net margin | -7.0% |
| Free cash flow | -$2.9 million |
| Diluted EPS | $-0.34 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +23% |
| Cash | $94.6 million |
| Long-term debt | $0 |
| Share count, 1 year | +17% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.